Pages that link to "Q64891783"

The following pages link to Rapamycin for immunosuppression in organ allografting. (Q64891783):

Displaying 50 items.

• Akt and mTOR in B Cell Activation and Differentiation (Q21131224) (← links)
• A Novel FK506 Binding Protein Can Mediate the Immunosuppressive Effects of FK506 and Is Associated with the Cardiac Ryanodine Receptor (Q24315855) (← links)
• The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin (Q24561472) (← links)
• Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS) (Q24685850) (← links)
• Exploiting the Biosynthetic Potential of Type III Polyketide Synthases (Q26747526) (← links)
• Cancer wars: natural products strike back (Q26850074) (← links)
• Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein (Q27934061) (← links)
• mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging (Q28081442) (← links)
• Rapamycin inhibits proteasome activator expression and proteasome activity (Q28256162) (← links)
• Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib (Q28765488) (← links)
• The TOR pathway: a target for cancer therapy (Q29614242) (← links)
• Development of a high-throughput cell-based reporter assay to identify stabilizers of tumor suppressor Pdcd4. (Q30878777) (← links)
• Clinical pharmacokinetics of everolimus (Q33358752) (← links)
• Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects (Q33393707) (← links)
• Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy (Q33435113) (← links)
• Surgical biology for the clinician: vascular effects of immunosuppression (Q33604754) (← links)
• The potential role of rapamycin in pediatric transplantation as observed from adult studies (Q33732940) (← links)
• Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and inducing apoptosis of endothelial progenitor cells (Q33776274) (← links)
• ScFKBP12 bridges rapamycin and AtTOR in Arabidopsis (Q33931994) (← links)
• Pharmacodynamics of immunosuppressive drugs (Q34046840) (← links)
• Lipidomic assessment of plasma and placenta of women with early-onset preeclampsia. (Q34362275) (← links)
• Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling (Q34391120) (← links)
• The limitations of calcineurin and mTOR inhibitors: new directions for immunosuppressive strategies (Q34604689) (← links)
• Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model (Q34740561) (← links)
• A retrospective review of sirolimus (Rapamune) therapy in orthotopic liver transplant recipients diagnosed with chronic rejection (Q35125083) (← links)
• The development of immunosuppression: the rapamycin milestone (Q35125751) (← links)
• The Rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation (Q35125756) (← links)
• Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation (Q35125786) (← links)
• Preclinical results of sirolimus treatment in transplant models (Q35125793) (← links)
• Immunomodulators. Future prospects (Q35530709) (← links)
• Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency (Q35617480) (← links)
• Sirolimus: a ten-year perspective (Q35687830) (← links)
• Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis. (Q35690750) (← links)
• The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL (Q35850028) (← links)
• Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors (Q36088857) (← links)
• The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin (Q36231731) (← links)
• Inhibition by rapamycin of leukocyte migration and bronchial hyperreactivity induced by injection of Sephadex beads to guinea-pigs (Q36330084) (← links)
• Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years (Q36357466) (← links)
• Everolimus: a review of its use in renal and cardiac transplantation (Q36441466) (← links)
• The mTOR pathway in breast cancer (Q36561728) (← links)
• Drug insight: novel small molecules and drugs for immunosuppression. (Q36636145) (← links)
• Rapamycin: FK506's fraternal twin or distant cousin? (Q36676047) (← links)
• The immunosuppressive macrolides FK-506 and rapamycin (Q36686159) (← links)
• Use of sirolimus in solid organ transplantation (Q36750090) (← links)
• Rapamycin: something old, something new, sometimes borrowed and now renewed (Q36922923) (← links)
• Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy (Q37035703) (← links)
• Proximity-Directed Labeling Reveals a New Rapamycin-Induced Heterodimer of FKBP25 and FRB in Live Cells (Q37209292) (← links)
• Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC. (Q37209537) (← links)
• Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases (Q37649641) (← links)
• Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment (Q37842326) (← links)